美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · SABS近 30 天 0 則 · 第 1 / 1 頁
- SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...
- SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
- SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
- Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
- Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
- Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
- SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
- Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
- We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully
- SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...
- SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
- Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
- SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
- SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。